Merz Aesthetics ® Announces Salma Hayek Pinault as First-Ever Global Brand Ambassador for Ultherapy PRIME, the Next Generation Platform for Nonsurgical Skin Lifting and Tightening Treatments
Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, is proud to announce world-renowned actress, director and producer, Salma Hayek Pinault, as the first-ever global brand ambassador for Ultherapy PRIME.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250409655489/en/
Redefining the future in medical aesthetics, Ultherapy PRIME is an advanced micro-focused ultrasound platform for personalized, non-invasive skin lifting and tightening.1,2 It is intended to lift and sculpt the skin of the upper face, lower face, neck and décolleté.1 It takes just one session, has no downtime, and delivers results that can last up to a year or more.1-3
With her unwavering commitment to authenticity, Salma Hayek Pinault trusts Ultherapy PRIME for a personalized, natural-looking lift, with results that can last up to a year or more .1-3 This collaboration reflects a shared belief in empowering individuals to look and feel their best to fuel confidence worldwide.
Salma Hayek Pinault is a highly acclaimed, Academy Award-nominated actress and Emmy-winning director, also celebrated for her work as a producer. She passionately advocates for causes that align with her core values and beliefs and has long supported several leading nonprofit organizations. As a strong advocate for authentic self-expression and looking great at any age, she encourages others to embrace treatments that enhance their natural features.
“Self-care is essential. Years on screen have taught me to embrace my journey and seek treatments that enhance my natural beauty,” said Salma Hayek Pinault. “Ultherapy PRIME boosts my production of collagen and elastin exactly where I need it*, giving me a long-lasting**, natural-looking lift. It's noninvasive, takes only one session, and has zero downtime. It is the future of beauty, and that’s why I can't stop talking about it."1-3,6
The Ultherapy PRIME platform is the evolution of Ultherapy® which has been recognized as the Gold Standard in non-invasive skin lifting and tightening.2 Built on Ultherapy®’s legacy of proven, natural-looking results, Ultherapy PRIMEredefines the future of nonsurgical skin lifting and tightening by uniquely combining an advanced micro-focused ultrasound platform with vivid real-time imaging.1 These advancements promote a safer and more effective, personalized lift that can last up to a year or more, paired with younger-looking skin.1-5
Since its September 2024 launch, Ultherapy PRIME has already been cleared in over 80% of our targeted markets, with more approvals expected in 2025.***
"We are proud and excited about the recent launch of Ultherapy PRIME, our next-generation platform for non-invasive skin lifting and tightening and a testament to our unwavering commitment to delivering meaningful innovations to our customers," said Bob Rhatigan, CEO of Merz Aesthetics®. "As we continue to expand the global footprint of this launch, we are thrilled to collaborate with Salma Hayek Pinault as the first-ever global brand ambassador for Ultherapy PRIME. At Merz Aesthetics® we empower individuals to embrace their unique beauty with confidence, and our collaboration with Salma Hayek Pinault compellingly embodies this purpose.”
To learn more and find a provider near you, visit Ultherapy.com. Follow @Ultherapy on Instagram for the latest news from Ultherapy PRIME and Hayek Pinault.
About Merz Aesthetics®
Merz Aesthetics® is a medical aesthetics business with a long history of empowering health care professionals, patients, and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves – however they define it. Clinically proven, its product portfolio includes injectables and devices designed to meet each patient’s needs Being family owned for more than 115 years, Merz Aesthetics® is known for building unique connections with customers who feel like family. Merz Aesthetics®’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
About Ultherapy®
The noninvasive Ultherapy® procedure is intended for dermatological sculpting and lifting of the dermis on the upper face, lower face, neck and décolleté. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product information.
* The exact skin depth targeting occurs due to real-time visualization
**lasts up to a year or more
***Ultherapy PRIME is currently unavailable in China, India, Azerbaijan, Russia, Costa Rica, Dominican Republic, Guatemala, Mexico, Peru, Uruguay, Iraq, Israel, Jordan, Lebanon
References:
- Ulthera® Instructions for Use.
- Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
- Werschler WP, Werschler PS. Longterm efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
- Pavicic T, Ballard JR, Bykovskaya T, et al. Microfocused ultrasound with visualization: consensus on safety and review of energy-based devices. J Cosmet Dermatol. 2022;21(2):636-647.
- Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
- Marquardt K, Hartmann C, Wegener F, Park JY, Halbert D, Hsu S, Hengl T. Microfocused Ultrasound With Visualization Induces Remodeling of Collagen and Elastin Within the Skin. J Cosmet Dermatol. 2025 Jan;24(1):e16638
© 2025 Ulthera, Inc. All Rights Reserved. MERZ AESTHETICS® is a trademark and/or registered trademark of Merz Pharma GmbH & Co. KGaA in the U.S. and/or certain other countries. ULTHERA, ULTHERAPY, and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera, Inc. in the U.S. and/or certain other countries.
Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and international patents to which Ulthera, Inc. has rights are issued, published, or pending.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250409655489/en/
Contacts
Media Contact
Merz Aesthetics®
Global Corporate Communications
6501 Six Forks Road, Raleigh NC 27615
919-302-3296
media@merz.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcts.businesswi
re.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dmailto%253A%252520media%2540merz.com%2
6esheet%3D54233560%26lan%3Den-US%26anchor%3Dmedia%2540merz.com%26index%3D3%26md5
%3D3235cfec4a5c30f18dfe762506c5dbc1&esheet=54233560&newsitemid=20250409655489&la
n=en-US&anchor=media%40merz.com&index=5&md5=1e3beed262b8f35333c21d285a109647
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande
Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press Release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr
Anabranch Capital Management, LP supports relisting of SmartCraft ASA to Nasdaq Stockholm12.12.2025 16:26:00 CET | Press Release
Reference is made to the stock exchange announcement by SmartCraft ASA ("SmartCraft" or the "Company") on 1 December 2025 regarding the contemplated relisting of SmartCraft from Euronext Oslo Børs to Nasdaq Stockholm (the "Relisting") and the announcement of a cross-border merger to effect the Relisting. Funds managed by Anabranch Capital Management, LP (“Anabranch”) intend to vote in favour of the merger plan resolved by the boards of SmartCraft and its Swedish wholly owned subsidiary, SmartCraft Group AB (publ), to effect the Relisting at the Company's extraordinary general meeting planned for January 2025 (the "EGM"). Anabranch intends to vote with all Anabranch shares held at the Record Date for the EGM in favour of the relisting effected by the merger plan. Funds managed by Anabranch currently hold approximately 15.9 million shares in SmartCraft. Disclaimer: The views expressed are those of the authors and Anabranch Capital Management, LP as of the date referenced and are subject
Mohammed Ben Sulayem Re-Elected as President of the FIA12.12.2025 15:49:00 CET | Press Release
The Fédération Internationale de l’Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, today confirms that Mohammed Ben Sulayem has been re-elected as President of the FIA, following the election of his Presidential List by the General Assembly in Tashkent, Republic of Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251212213181/en/ President Mohammed Ben Sulayem now begins his second four-year term, having overseen a period of significant renewal and stabilisation for the organisation since his initial election in 2021. Over the past four years, the FIA has undergone a wide-ranging transformation, improving governance, operations and restoring the financial health of the federation. These changes have strengthened the FIA’s position as the world’s governing body for motorsport and the leading authority on safe, sustainable, and affordable mobility.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom